Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
BIOCON | GSK PHARMA | BIOCON / GSK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 33.1 | 50.2 | 65.9% | View Chart |
P/BV | x | 3.9 | 11.3 | 34.8% | View Chart |
Dividend Yield | % | 0.2 | 1.4 | 17.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-19 |
GSK PHARMA Mar-19 |
BIOCON / GSK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 707 | 3,595 | 19.7% | |
Low | Rs | 554 | 1,253 | 44.2% | |
Sales per share (Unadj.) | Rs | 91.9 | 184.7 | 49.8% | |
Earnings per share (Unadj.) | Rs | 16.7 | 26.3 | 63.6% | |
Cash flow per share (Unadj.) | Rs | 24.2 | 29.2 | 82.9% | |
Dividends per share (Unadj.) | Rs | 1.00 | 20.00 | 5.0% | |
Dividend yield (eoy) | % | 0.2 | 0.8 | 19.2% | |
Book value per share (Unadj.) | Rs | 101.6 | 126.3 | 80.5% | |
Shares outstanding (eoy) | m | 600.00 | 169.40 | 354.2% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 6.9 | 13.1 | 52.3% | |
Avg P/E ratio | x | 37.7 | 92.2 | 40.9% | |
P/CF ratio (eoy) | x | 26.1 | 83.1 | 31.4% | |
Price / Book Value ratio | x | 6.2 | 19.2 | 32.3% | |
Dividend payout | % | 6.0 | 76.1 | 7.9% | |
Avg Mkt Cap | Rs m | 378,330 | 410,626 | 92.1% | |
No. of employees | `000 | 6.1 | 5.0 | 123.6% | |
Total wages/salary | Rs m | 11,653 | 5,372 | 216.9% | |
Avg. sales/employee | Rs Th | 8,994.3 | 6,306.7 | 142.6% | |
Avg. wages/employee | Rs Th | 1,900.7 | 1,083.1 | 175.5% | |
Avg. net profit/employee | Rs Th | 1,635.3 | 898.0 | 182.1% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 55,144 | 31,281 | 176.3% | |
Other income | Rs m | 1,444 | 1,023 | 141.1% | |
Total revenues | Rs m | 56,588 | 32,304 | 175.2% | |
Gross profit | Rs m | 15,883 | 6,009 | 264.3% | |
Depreciation | Rs m | 4,478 | 486 | 921.4% | |
Interest | Rs m | 709 | 6 | 11,816.7% | |
Profit before tax | Rs m | 12,140 | 6,540 | 185.6% | |
Minority Interest | Rs m | 9 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 287 | 0.0% | |
Tax | Rs m | 2,123 | 2,373 | 89.5% | |
Profit after tax | Rs m | 10,026 | 4,454 | 225.1% | |
Gross profit margin | % | 28.8 | 19.2 | 149.9% | |
Effective tax rate | % | 17.5 | 36.3 | 48.2% | |
Net profit margin | % | 18.2 | 14.2 | 127.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 48,228 | 20,061 | 240.4% | |
Current liabilities | Rs m | 30,376 | 14,543 | 208.9% | |
Net working cap to sales | % | 32.4 | 17.6 | 183.5% | |
Current ratio | x | 1.6 | 1.4 | 115.1% | |
Inventory Days | Days | 68 | 57 | 120.3% | |
Debtors Days | Days | 86 | 14 | 608.1% | |
Net fixed assets | Rs m | 64,130 | 14,343 | 447.1% | |
Share capital | Rs m | 3,000 | 1,694 | 177.1% | |
"Free" reserves | Rs m | 57,980 | 19,704 | 294.3% | |
Net worth | Rs m | 60,980 | 21,398 | 285.0% | |
Long term debt | Rs m | 15,766 | 2 | 788,300.0% | |
Total assets | Rs m | 121,924 | 39,113 | 311.7% | |
Interest coverage | x | 18.1 | 1,091.0 | 1.7% | |
Debt to equity ratio | x | 0.3 | 0 | 276,619.7% | |
Sales to assets ratio | x | 0.5 | 0.8 | 56.6% | |
Return on assets | % | 8.8 | 11.4 | 77.2% | |
Return on equity | % | 16.4 | 20.8 | 79.0% | |
Return on capital | % | 16.8 | 31.9 | 52.5% | |
Exports to sales | % | 28.1 | 0 | - | |
Imports to sales | % | 18.9 | 0 | - | |
Exports (fob) | Rs m | 15,506 | NA | - | |
Imports (cif) | Rs m | 10,399 | NA | - | |
Fx inflow | Rs m | 15,506 | 534 | 2,903.7% | |
Fx outflow | Rs m | 10,399 | 7,091 | 146.7% | |
Net fx | Rs m | 5,107 | -6,557 | -77.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 11,546 | 3,994 | 289.1% | |
From Investments | Rs m | -7,138 | -1,433 | 498.0% | |
From Financial Activity | Rs m | -2,417 | -3,584 | 67.4% | |
Net Cashflow | Rs m | 2,103 | -1,023 | -205.5% |
Indian Promoters | % | 40.4 | 0.0 | - | |
Foreign collaborators | % | 20.6 | 50.7 | 40.6% | |
Indian inst/Mut Fund | % | 8.4 | 10.2 | 82.4% | |
FIIs | % | 10.7 | 23.8 | 45.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 19.9 | 15.4 | 129.2% | |
Shareholders | 109,995 | 102,036 | 107.8% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: PANACEA BIOTECH DIVIS LABORATORIES FULFORD INDIA NATCO PHARMA ELDER PHARMA
Compare BIOCON With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video I tell you the three Nifty ETFs I think are the best.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
More